While studies with SGLT2 inhibitors have been conducted almost entirely in the diabetes, this drug class lowers tubular glucose reabsorption sufficiently to induce glycosuria in both animal models and human subjects without hyperglycaemia [12–16]. The gene discussed is SLC5A2; the disease is diabetes mellitus.